Standout Papers

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results 2023 2026 2024149
  1. Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results (2023)
    Sham Mailankody, Jeffrey Matous et al. Nature Medicine

Immediate Impact

1 from Science/Nature 57 standout
Sub-graph 1 of 23

Citing Papers

The interaction of innate immune and adaptive immune system
2024 Standout
Past, present, and future of CRISPR genome editing technologies
2024 Standout
2 intermediate papers

Works of Wade Lovelace being referenced

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
2023 Standout

Author Peers

Author Last Decade Papers Cites
Wade Lovelace 334 131 58 114 6 372
Ifigenia Tzannou 238 30 80 97 7 412
Roel Polak 77 113 51 16 9 413
Phillip George 112 46 20 25 10 450
Elliot Perlin 189 20 64 20 8 343
J.D. Eaton 92 191 75 69 7 345
Carla Kreissig 173 102 87 61 11 352
Angela Sullivan 164 222 90 54 8 376
C R Harman 219 109 36 39 11 392
Daniel L. Sprague 76 165 141 37 6 451
Scott Melvin 149 164 81 35 10 441

All Works

Loading papers...

Rankless by CCL
2026